Zydus Cadila flagship firm Cadila Healthcare Ltd. has received marketing approval from the Drugs Controller General of India for its new chemical entity saroglitazar, to treat non-cirrhotic, non-alcoholic steatohepatitis (NASH), making it the first treatment to be approved for the condition globally and placing the Ahmedabad-based firm in the lead, for now, in a segment brimming with competition.
Pricing for the drug, to be launched three months from now, hasn’t been decided yet, Cadila chairman Pankaj Patel told...







